HilleVax (NASDAQ:HLVX - Get Free Report) is anticipated to post its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter.
HilleVax (NASDAQ:HLVX - Get Free Report) last announced its quarterly earnings results on Friday, March 28th. The company reported ($0.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.02). On average, analysts expect HilleVax to post $-3 EPS for the current fiscal year and $-2 EPS for the next fiscal year.
HilleVax Trading Up 0.7 %
NASDAQ:HLVX traded up $0.01 on Tuesday, hitting $1.93. The company had a trading volume of 81,774 shares, compared to its average volume of 445,788. The firm has a 50 day moving average of $1.70 and a two-hundred day moving average of $1.84. The stock has a market capitalization of $96.97 million, a price-to-earnings ratio of -0.62 and a beta of 0.78. HilleVax has a 52 week low of $1.34 and a 52 week high of $16.31.
Analyst Ratings Changes
Separately, HC Wainwright reissued a "neutral" rating and set a $2.00 price target on shares of HilleVax in a research note on Monday, March 31st. Six equities research analysts have rated the stock with a hold rating, According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $3.00.
View Our Latest Analysis on HLVX
About HilleVax
(
Get Free Report)
HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.
Further Reading
Before you consider HilleVax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HilleVax wasn't on the list.
While HilleVax currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
